Predicting toxicities in humans by nonclinical safety testing: an update with particular reference to anticancer compounds

Drug Discovery Today

Volumn 22, Issue 1, 2017, Pages 127-132

  Ahuja, Varun ^a   Bokan, Sanjay ^a   Sharma, Sharad ^a  

^a LUPIN LIMITED   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOVASCULAR TOXICITY; DRUG SAFETY; DRUG TOXICITY; ENDOCRINE TOXICITY; EYE TOXICITY; FOOD AND DRUG ADMINISTRATION; HEPATOBILIARY TOXICITY; HUMAN; IMMUNOTOXICITY; INTEGUMENTARY TOXICITY; LIVER TOXICITY; LYMPHOID TOXICITY; MUSCULOSKELETAL TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; RESPIRATORY TOXICITY; REVIEW; SENSITIVITY AND SPECIFICITY; TOXICITY; TOXICITY TESTING; ANIMAL; PRECLINICAL STUDY; PREDICTIVE VALUE; PROCEDURES; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; PREDICTIVE VALUE OF TESTS; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 84995616669     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.09.007     Document Type: Review

References (41)

1. 1 Fletcher, A.P., Drug safety tests and subsequent clinical experience. J. R. Soc. Med. 71 (1978), 693–696.
2. 2 Olson, H., et al. Concordance of the toxicity of pharmaceuticals in humans and animals. Regul. Toxicol. Pharmacol. 32 (2000), 56–67.
3. 3 Igarashi, T., The duration of toxicity studies required to support repeated dosing in clinical investigation – a toxicologists opinion. Parkinson, C., et al. (eds.) The Timing of Toxicological Studies to Support Clinical Trials, 1994, Springer, 67–74.
4. 4 Schein, P.S., et al. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11 (1970), 3–40.
5. 5 Owens, A.H., Predicting anticancer drug effects in man from laboratory animal studies. J. Chron. Dis. 15 (1962), 223–228.
6. 6 Freireich, E.J., et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50 (1966), 219–244.
7. 7 Greaves, P., et al. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 3 (2004), 226–236.
8. 8 Igarashi, T., et al. Predictability of clinical adverse reactions of drugs by general pharmacology studies. J. Toxicol. Sci. 20 (1995), 77–92.
9. 9 Shibuya, K., et al. Characteristics of structures and lesions of the eye in laboratory animals used in toxicity studies. J. Toxicol. Pathol. 28 (2015), 181–188.
10. 10 Valentin, J.P., et al. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 60 (2010), 152–158.
11. 11 Authier, S., et al. Safety Pharmacology investigations on the nervous system: an industry survey. J. Pharmacol. Toxicol. Methods, 2016 Published online June 2, 2016. http://dx.doi.org/10.1016/j.vascn.2016.06.001.
12. 12 Perez, J., Perentes, E., Light-induced retinopathy in the albino rat in long-term studies. An immunohistochemical and quantitative approach. Exp. Toxicol. Pathol. 46 (1994), 229–235.
13. 13 Ettlin, R.A., et al. Successful drug development despite adverse preclinical findings. Part 2: examples. J. Toxicol. Pathol. 23 (2010), 213–234.
14. 14 Li, J., et al. Drug-induced ocular disorders. Drug Saf. 31 (2008), 127–141.
15. 15 Huang, W., et al. Application of electroretinography (ERG) in early drug development for assessing retinal toxicity in rats. Toxicol. Appl. Pharmacol. 289 (2015), 525–533.
16. 16 Eichenbaum, G., et al. Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate. Regul. Toxicol. Pharmacol. 69 (2014), 187–200.
17. 17 Hanton, G., Preclinical cardiac safety assessment of drugs. Drugs R. D. 8 (2007), 213–228.
18. 18 Orphanos, G.S., et al. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 48 (2009), 964–970.
19. 19 Clemo, F.A., et al. Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol. Pathol. 31 (2003), 25–31.
20. 20 Jokinen, M.P., et al. Characterization of spontaneous and chemically induced cardiac lesions in rodent model systems: the national toxicology program experience. Cardiovasc. Toxicol. 5 (2005), 227–244.
21. 21 Sandusky, G.E., et al. Comparative cardiovascular toxicity in dogs given inotropic agents by continuous intravenous infusion. Toxicol. Pathol. 18 (1990), 268–278.
22. 22 Dogterom, P., et al. Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. Crit. Rev. Toxicol. 22 (1992), 203–241.
23. 23 Rozencweig, M., et al. Animal toxicology for early clinical trials with anticancer agents. Cancer Clin. Trials 4 (1981), 21–28.
24. 24 Cardenas, J.C., et al. Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 827–833.
25. 25 Brown, A.P., et al. Administration of a MEK inhibitor results in tissue mineralization in the rat due to dysregulation of phosphorus and calcium homeostasis. Toxicologist, 84, 2005, 108.
26. 26 Dwivedi, P.P., et al. Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. J. Biol. Chem. 277 (2002), 29643–29653.
27. 27 Hamamoto, H., et al. Structure-function analysis of vitamin D 24-hydroxylase (CYP24A1) by site-directed mutagenesis: amino acid residues responsible for species-based difference of CYP24A1 between humans and rats. Mol. Pharmacol. 70 (2006), 120–128.
28. 28 Hayes, A.W., et al. Correlation of human hepatotoxicants with hepatic damage in animals. Fundam. Appl. Toxicol. 2 (1982), 55–66.
29. 29 Dorato, M., Vodicinik, M., The toxicological assessment of pharmaceutical and biotechnology products. Hayes, A., (eds.) Principles and Methods of Toxicology, 4th edn, 2001, Taylor & Francis, 243–283.
30. 30 Hawke, T.J., Garry, D.J., Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. 91 (2001), 534–551.
31. 31 Koleva, M., et al. Pleiotropic effects of sonic hedgehog on muscle satellite cells. Cell Mol. Life Sci. 62 (2005), 1863–1870.
32. 32 Jin, Z., et al. HDAC9 inhibits osteoclastogenesis via mutual suppression of PPARγ/RANKL signaling. Mol. Endocrinol. 29 (2015), 730–738.
33. 33 Eremina, V., et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358 (2008), 1129–1136.
34. 34 Ribelin, W.E., The effects of drugs and chemicals upon the structure of the adrenal gland. Fundam. Appl. Toxicol. 4 (1984), 105–119.
35. 35 Rane, S.G., et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet. 22 (1999), 44–52.
36. 36 Martin, J., et al. Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22 (2003), 5261–5269.
37. 37 Dean, J.H., Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. Toxicology 119 (1997), 95–101.
38. 38 Dean, J.H., et al. Immunotoxicology assessment in the pharmaceutical industry. Toxicol. Lett. 102-103 (1998), 247–255.
39. 39 Spanhaak, S., The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: Autonomous or synergistic methods to predict immunotoxicity?. Exp. Toxicol. Pathol. 57 (2006), 373–376.
40. 40 Descotes, J., Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system. J. Pharmacol. Toxicol. Methods 66 (2012), 79–83.
41. 41 Ettlin, R.A., et al. Successful drug development despite adverse preclinical findings. Part 1: Processes to address issues and most important findings. J. Toxicol. Pathol. 23 (2010), 189–211.